"The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafenib) to treat patients with advanced gastrointestinal stromal tumors (GIST) that cannot be surgically removed and no longer respond to other FDA-approved t"...
- Inform patients that allergic reactions, including potentially serious reactions, may occur during VORAXAZE treatment.
- Advise patients to immediately report any signs and symptoms of infusion reactions such as fever, chills, flushing, feeling hot, rash, hives, itching, throat tightness or breathing problems, tingling, numbness, or headache.
- Inform patients of the importance of continued monitoring of methotrexate blood concentrations and renal status at the appropriate times after discharge from the hospital.
Last reviewed on RxList: 4/15/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional Voraxaze Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.